8 Result(s)
within
Larry H. Matherly
Biomedicine
-
Article
Lipid metabolism reprogramming in renal cell carcinoma
Metabolic reprogramming is recognized as a hallmark of cancer. Lipids are the essential biomolecules required for membrane biosynthesis, energy storage, and cell signaling. Altered lipid metabolism allows tumo...
-
Article
Open AccessImpact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds
Expression of proton-coupled folate transporter (PCFT) is associated with survival of mesothelioma patients treated with pemetrexed, and is reduced by hypoxia, prompting studies to elucidate their correlation.
-
Article
Open AccessFolate receptors and transporters: biological role and diagnostic/therapeutic targets in cancer and other diseases
Folate receptors and transporters and one-carbon metabolism continue to be important areas of study given their essential roles in an assortment of diseases and as targets for treatment of cancer and inflammat...
-
Chapter
Biological Role, Properties, and Therapeutic Applications of the Reduced Folate Carrier (RFC-SLC19A1) and the Proton-Coupled Folate Transporter (PCFT-SLC46A1)
The mechanisms by which folates are transported across cell membranes have been an area of research interest for nearly five decades. Major transport systems include the facilitative carriers, the reduced fola...
-
Chapter
Discovery of Novel Antifolate Inhibitors of De Novo Purine Nucleotide Biosynthesis with Selectivity for High Affinity Folate Receptors and the Proton-Coupled Folate Transporter Over the Reduced Folate Carrier for Cellular Entry
Lack of drug selectivity is one of the major causes of the failure of cancer chemotherapy. This Chapter describes studies that explore the concept of therapeutic targeting solid tumors using folate-receptor (F...
-
Article
Preface
-
Article
Human reduced folate carrier: translation of basic biology to cancer etiology and therapy
This review attempts to provide a comprehensive overview of the biology of the physiologically and pharmacologically important transport system termed the “reduced folate carrier” (RFC). The ubiquitously expre...
-
Chapter
Determinants of the Disparate Antitumor Effects of (6R)5,10-Dideaza-5,6,7,8-Tetrahydrofolate and Methotrexate Toward Methotrexate Resistant CCRF-CEM Cells, Characterized by Severely Impaired Antifolate Membrane Transport
The antifolate, (6R) 5,10-dideaza-5,6,7,8-tetrahydrofolate (DDATHF), derives its antitumor effects by inhibiting 5’-phosphoribosylglycinamide (GAR) transformylase1, the first folate-dependent enzyme in the de nov...
